Responses
Clinical/translational cancer immunotherapy
Original research
CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression
Compose a Response to This Article
Other responses
No responses have been published for this article.
